{"id":"placebo-extended-release-microspheres","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108492","moleculeType":"Protein"},"_fixedAt":"2026-03-30T12:11:30.150985","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease.","oneSentence":"This drug is a placebo, meaning it has no active therapeutic effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:52.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(2)"],"trialDetails":[{"nctId":"NCT04331002","phase":"PHASE2","title":"Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury","status":"TERMINATED","sponsor":"Austin V Stone","startDate":"2020-08-21","conditions":"Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn","enrollment":1},{"nctId":"NCT04571164","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-05-11","conditions":"Parkinson Disease","enrollment":294},{"nctId":"NCT04627155","phase":"PHASE1","title":"A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2013-03-15","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT01882361","phase":"PHASE2, PHASE3","title":"Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-06","conditions":"Opiate Dependence, Human Immunodeficiency Virus","enrollment":77},{"nctId":"NCT04045678","phase":"PHASE1","title":"A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT04044547","phase":"PHASE1","title":"A Study of LY03003 in Patients With Early-stage Parkinson's Disease","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2013-11-22","conditions":"Parkinson Disease","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo, extended-release microspheres","genericName":"Placebo, extended-release microspheres","companyName":"Luye Pharma Group Ltd.","companyId":"luye-pharma-group-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo is a type of extended-release microspheres used as a control intervention in clinical trials. It is not a drug with a known mechanism, but rather a neutral treatment used for comparison purposes in studies examining conditions such as tibial meniscus injuries and Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}